Value repeatedly verified! Medicilon congratulates its partner, EpimAb Biotherapeutics, on the overseas authorization of their BCMA×CD3 bispecific antibody EMB-06

On September 4^th, EpimAb Biotherapeutics (EpimAb) announced that it has reached a licensing agreement with Vignette Bio, Inc. (Vignette Bio) regarding EpimAb’s BCMA-targeted T-cell engager (TCE) molecule, EMB-06. Under the agreement, EpimAb grants Vignette Bio exclusive rights to develop and commercialize EMB-06 outside the Greater China region (including mainland China, Hong Kong, Macau, and Taiwan), while EpimAb retains rights to EMB-06 within the Greater China region. EpimAb will receive an upfront payment totaling $60 million in cash and Vignette Bio equity, and will be entitled to up to $575 million in development, regulatory, and commercialization milestone payments, as well as revenue sharing based on net sales.

On September 9^th, Candid Therapeutics announced the completion of a $370 million Series A funding round. Through a three-party merger and multi-step financing, Candid Therapeutics acquired Vignette Bio and TRC 2004, obtaining Vignette's BCMA×CD3 bispecific antibody and TRC 2004's CD3×CD20 bispecific antibody. This further confirms the advanced nature of EpimAb's T-cell engager platform and the broad recognition and high valuation of its BCMA×CD3 bispecific antibody in the industry.

As a partner of EpimAb, Shanghai Medicilon Inc. (Medicilon) congratulates EpimAb on the licensing of its BCMA×CD3 bispecific antibody EMB-06 for international markets. In EpimAb's innovative journey, Medicilon has provided essential services for the CD3/ROR1 bispecific antibody EMB-07 injection (currently in Phase I clinical trials) through its specialized antibody drug development service platform. These services, including pharmacokinetics and safety evaluations, have offered solid support for the successful advancement of the project.2 major bispecific antibody technology platforms, 3 oncology fields, 5 clinical projects. EpimAb frequently achieves external licensing collaborations due to its technical strength

EpimAb stands out in the biopharmaceutical field due to its strong technical capabilities. The company possesses two proprietary bispecific antibody technology platforms—FIT-Ig® and MAT-Fab—which precisely cover three strategic oncology fields: tumor targeting, dual immune checkpoints, and immune cell guidance. FIT-Ig®, as a unique global bispecific antibody technology, does not require amino acid mutations, does not include linker peptide chains or non-antibody sequences, and offers high druggability and industrialization efficiency. It has been granted patent authorization in several major markets worldwide.

Leveraging these two platforms, EpimAb has launched five clinical projects and more than ten preclinical candidates, demonstrating its strong drive for continuous innovation and leadership in the industry. The successful international licensing of the EMB-06 bispecific antibody further proves EpimAb's technical strength and market potential.

Notably, EpimAb has established extensive collaborations with several renowned domestic and international pharmaceutical and biotechnology companies, including Innovent Bio, Kymab, Teruisi, and Almirall. These partnerships leverage its outstanding antibody technology platforms to advance the development and application of bispecific antibody technologies. These collaborations not only bring valuable resources and market opportunities to EpimAb but also further solidify its leading position in the bispecific antibody field.

Medicilon Antibody Drug R&D Service Platform
One-Stop Support for Preclinical Development of Antibody Drugs

Currently, the field of antibody drugs is experiencing a golden period of rapid development. With their highly precise targeting characteristics and exceptional potential for innovative therapies, antibody drugs are leading the forefront of exploration in the biopharmaceutical industry. In this field, not only has EpimAb stood out with its strong foundation and innovative capabilities, but Medicilon, as an enabler of antibody drug research and development, is also deeply committed to advancing progress in this area.

In the field of antibodies, Medicilon provides comprehensive preclinical R&D services, including drug discovery, CMC research services, and GLP-compliant preclinical research services (such as pharmacodynamic studies, pharmacokinetic evaluations, and safety assessments).  As of April 2024, Medicilon has successfully assisted in obtaining clinical approval for 34 antibodies, including monoclonal, bispecific, and trispecific antibodies. Among these, 6 antibody drugs were approved simultaneously by both the FDA and NMPA, 3 by both NMPA and TGA, and 1 by the FDA, NMPA, and TGA. Additionally, multiple antibody projects are currently in development.

About EMB-06

EMB-06 is a recombinant humanized bispecific antibody targeting both BCMA (B-cell maturation antigen) and CD3. By binding to BCMA expressed on the surface of tumor cells and activating T cells, EMB-06 can mediate the specific killing of BCMA-expressing tumor cells. Currently, a global Phase I/II clinical trial is underway in Australia and China.

About EMB-07

EMB-07 is a T-cell-redirecting bispecific antibody that targets a novel tumor-associated antigen (ROR1) and CD3. The molecular design of EMB-07 is based on the MAT-Fab technology platform. By bridging tumor cells and T cells and activating T cells, EMB-07 mediates the specific killing of solid tumors by T cells. In preclinical studies, EMB-07 has demonstrated promising efficacy and safety.

About EpimAb Biotherapeutics

EpimAb Biotherapeutics is a clinical-stage biopharmaceutical company specializing in the development of multispecific antibodies. Leveraging its extensive internal research and technological capabilities, including proprietary bispecific antibody technology platforms FIT-Ig® (Fabs-In-Tandem Immunoglobulin) and MAT-Fab (Monovalent Asymmetric Tandem Fab), EpimAb Biotherapeutics is launching and globally advancing a series of unique pipeline projects. These include innovative preclinical and clinical-stage programs aimed at benefiting cancer patients. Please visit www.epimab.com for more information.

About Medicilon

Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China.  Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research.  Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support.  By the end of June 2024, Medicilon has provided new drug R&D services to more than 2,000 clients around the world, and participated in the R&D of 490 new drug projects that have been approved for clinical trials.  Medicilon is proud to contribute to human health in the globe.